EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results.

Charles  Drescher

Leadership - Powell-Drescher Ovarian Cancer Research Foundation; Rivkin Center; Swedish Cancer Center

Research Funding - Canary Foundation; National Cancer Institute

Harriet S.  Walter

Honoraria - AstraZeneca; BeiGene; Genmab; Loxo

Consulting or Advisory Role - BeiGene; Genmab; Loxo

Research Funding - Gilead Sciences; Pfizer

Thomas  Gastinne

Consulting or Advisory Role - BMS; Kite, a Gilead company; Novartis; Takeda

Travel, Accommodations, Expenses - Kite, a Gilead company; Takeda

Nehal J.  Lakhani

Consulting or Advisory Role - Ikena Oncology; SK Life Sciences

Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)

Vincent  Ribrag

Honoraria - Abbvie; AZD; Gilead Sciences; Infinity Pharmaceuticals; NanoString Technologies; Novartis; roche

Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Immune Design; Incyte; Infinity Pharmaceuticals; MSD; NanoString Technologies; PharmaMar; Roche; Roche/Genentech

Research Funding - arGEN-X BVBA; argenx (Inst); Astex Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline/Adaptimmune (Inst)

Expert Testimony - SERVIER

Travel, Accommodations, Expenses - azd; AZD; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche

Drew W.  Rasco

Research Funding - 23andMe (Inst); Abbvie (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Cullinan Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)

Martin  Gutierrez

Stock and Other Ownership Interests  - Cota Healthcare

Speakers' Bureau - BMS; Lilly; Merck

Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)

Travel, Accommodations, Expenses - Guardant Health

Ryan J.  Sullivan

Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune

Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)

R. Donald  Harvey

Consulting or Advisory Role - Amgen; Erasca, Inc; Janssen Oncology

Research Funding - Abbisko (Inst); Abbvie (Inst); ADC Therapeutics; GlaxoSmithKline (Inst); Incyte; Janssen Research & Development (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); MorphoSys; Nektar (Inst); Takeda (Inst); Xencor (Inst)

Kalyan  Banda

Honoraria - GlaxoSmithKline

Research Funding - Lilly; MorphoSys

Michal  Kwiatek

No Relationships to Disclose

Alejandro Martin  Garcia-Sancho

Honoraria - Celgene; Eusa Pharma; Gilead Sciences; Janssen-Cilag; Novartis; Roche; SERVIER; Takeda

Consulting or Advisory Role - ADC Therapeutics; BMS; EUSA Pharma; Gilead Sciences; Incyte; iQONE; Kyowa Hakko Kirin; Lilly; Miltenyi Biomedicine; MorphoSys; Novartis; Roche; SERVIER

Research Funding - Janssen (Inst); Teva (Inst)

Expert Testimony - Gilead Sciences

Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen Oncology; Kern Pharma; Roche; SERVIER

Linda R.  Duska

Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron

Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)

Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate

Pier Luigi  Zinzani

Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics

Speakers' Bureau - EUSA Pharma; MSD; Novartis

Anjali  Thakur

Employment - MorphoSys

Lennart  Kann

Employment - MorphoSys

Stock and Other Ownership Interests  - MorphoSys

Nicola  Faulhaber

Employment - MorphoSys

Julia  Jauch-Lembach

No Relationships to Disclose

Hedy L.  Kindler

Consulting or Advisory Role - AstraZeneca; Bluestar Genomics; Deciphera; Inhibrx; Sanofi; Seagen; Tempus

Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Deciphera (Inst); Fibrogen (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Polaris (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); Verastem (Inst); Vivace Therapeutics (Inst)